Tag: Africa

Posted on

Quantexa Appoints Industry Luminaries to its Advisory Board to Accelerate Growth Plans

Former president of BlackRock, former CEO of NHSX, and former Director of GCHQ bring wealth of industry experience from finance, healthcare, and national security

LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) — Quantexa, the global leader in Decision Intelligence (DI) solutions for the private and public sectors, announced today that it has appointed three industry luminaries to its Advisory Board. These hires include Ralph Schlosstein, former CEO of Evercore and former President of BlackRock, Matthew Gould, former CEO of NHSX, and Sir Jeremy Fleming, Former Director of GCHQ. These distinguished leaders bring a wealth of expertise in finance, healthcare, and national security to Quantexa.

The expansion of Quantexa’s Advisory Board comes at a pivotal time for the organization, following the completion of a $129 million Series E funding round, led by GIC, where Quantexa joined an elite group of UK tech companies reaching breakout unicorn status. It was also announced this year that Quantexa will invest over $155M in the global AI industry over the next three years to help clients advance the use of AI to protect, optimize, and grow their organizations. By 2027, Quantexa’s total global investment in AI will reach more than $250M.

Ralph Schlosstein, former CEO of Evercore and former President of BlackRock, brings decades of experience in investment banking to Quantexa’s Advisory Board. His distinguished career includes playing a strategic role in helping the world’s largest asset management firm go public. Ralph’s financial acumen will play a pivotal role in shaping corporate strategy initiatives.

Matthew Gould, former CEO of NHSX, joins Quantexa’s Advisory Board, after serving as the British ambassador to Israel between 2010 and 2015, where Gould helped to launch the UK-Israel Technologies Hub – an initiative run in Tel Aviv to forge technology partnerships between UK and Israeli companies. More recently, Matthew leveraged his extensive background in healthcare to play a pivotal role in advising NHS on initiatives throughout the Covid-19 pandemic. At NHSX, Gould has been responsible for harnessing the power of data and technology to improve healthcare delivery. Matthew’s deep expertise will help Quantexa identify the economies and industries for strategic focus and make decisions on commercial strategy.

Sir Jeremy Fleming, Former Director of GCHQ, and former Deputy Head of MI5, joins the Advisory Board with more than 30 years of experience in intelligence and technology. His extensive background includes developing the National Cyber Security Centre, where he strived to make the UK the safest place to live and do business online. With a passion for making technology use in government more transparent, Sir Fleming will enhance Quantexa’s capabilities in addressing emerging threats and opportunities.

“We are pleased to welcome Ralph Schlosstein, Matthew Gould, and Sir Jeremy Fleming to our Advisory Board,” said Vishal Marria, CEO of Quantexa. “Their collective expertise in finance, healthcare, and national security will be invaluable as we continue to develop cutting-edge decision intelligence solutions that address the evolving needs of the market.”

“Quantexa’s AI-enabled technology allows its customers to protect, optimize, and grow their organizations with efficiency and transparency,” said Ralph Schlosstein, former CEO of Evercore and former President of BlackRock. “I believe Quantexa is well-positioned to capture the opportunities ahead and increase its share of the emerging Decision Intelligence category. I am looking forward to supporting the executive team as they work to accelerate their organic and inorganic growth strategy.”

“It’s an exciting time for me to be joining Quantexa’s Advisory Board, at this critical stage of growth for the company,” said Matthew Gould. “Quantexa’s innovative approach to helping customers in the private and public sectors make data their most valuable utility is revolutionizing decision making across multiple industries. I look forward to working alongside the talented team at Quantexa to connect data and drive better outcomes for organizations.”

Sir Jeremy Fleming, Former Director of GCHQ commented “I’m thrilled to be part of a company at the forefront of AI innovation. I look forward to combining my experience with Quantexa’s impressive capabilities, which will continue to shape how their customers use data to protect businesses and citizens.”

With the help of its Advisory Board, Quantexa remains dedicated to empowering organizations to make trusted operational decisions through innovative Decision Intelligence solutions. For more on Quantexa’s Leadership team, visit here.

About Quantexa

Quantexa is a global data and analytics software company pioneering Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa’s Decision Intelligence platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 650 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, Dublin, New York, Boston, Washington DC, Toronto, UAE, Malaga, Amsterdam, Luxembourg, Brussels, Melbourne, Sydney, and Singapore. For more information, follow us on LinkedIn.

Media Inquiries:
C: Stephanie Crisp, Associate Director and Media Strategist, Fight or Flight
E: Quantexa@fightflight.co.uk

C: Adam Jaffe, SVP of Corporate Marketing
T: +1 609 502 6889
E: adamjaffe@quantexa.com  

GlobeNewswire Distribution ID 1000840648

Posted on

Duck Creek Technologies Announces Winners of Its Inaugural 2023 Duck Creek Technologies Partner of the Year Awards

Systems Integrator Partners Accenture, Aggne and Coforge; Solution Partners Copart, LexisNexis Risk Solutions, Quadient, and Smart Communications and Consulting Partner Penguin Tech are each recognized for meaningful technology innovations to the insurance industry during Duck Creek’s Partner Summit ’23

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, announces today the winners for the company’s inaugural 2023 Duck Creek Technologies Partner of the Year Awards during its annual Partner Summit ’23, held in Orlando, Florida, September 20-21, 2023. Receiving Duck Creek’s 2023 Partner of the Year Awards were Systems Integrator Partners Accenture, Aggne and Coforge; Solution Partners Copart, LexisNexis Risk Solutions, Smart Communications, and Quadient; and consulting partner Penguin Tech.

The SaaS (software-as-a-service) leader dedicated time during their event to recognize the incredible accomplishments of their solution partners, systems integrators and consulting partners worldwide. The Duck Creek Technologies Partner of the Year Awards were created to acknowledge the power of partnerships and celebrate significant joint achievements across the insurance ecosystem. Engraved glass awards were handed to the eight winners for achieving the highest level of excellence as a partner to Duck Creek and for having a vision to advance their business while reimagining the future of insurance.

Accenture was recognized as System Integrator Partner of the Year for excelling in joint go-to-market activities, delivering Duck Creek solutions to customers across the globe, and consistently exceeding delivery adherence standards.​ Accenture has achieved the highest number of completed implementations across Duck Creek solutions and maintains its position as a significant influence for global customer upsells.

Aggne was recognized as Americas Value Creation Partner of the Year for successful collaboration with Duck Creek sales teams to differentiate and win new business and development of accelerators to ensure successful migration of customers to Duck Creek OnDemand (DCOD).

Coforge was recognized as International Value Creation Partner of the Year for providing exceptional delivery of packaged services to customers, realizing faster time to value from Duck Creek.​ Coforge successfully deployed prepackaged Duck Creek OnDemand solutions using accelerators and best practices in record time.

Copart was recognized as Operational Efficiency Solution Partner of the Year for its integration with Duck Creek. It improves operational efficiency for our mutual customers, enabling them to make intelligent insurance decisions and quickly meet policyholders’ needs. Copart has been a valued go-to-market partner for Duck Creek in the top 10 auto insurer market and provides an industry-leading auto salvage service central to Duck Creek’s automotive claims strategy. Its robust integration with Duck Creek provides a demonstrable example of simultaneously improving operational efficiency and customer experience.

LexisNexis Risk Solutions was recognized as Speed-to-Market Solution Partner of the Year for its integrations with Duck Creek, significantly impacting our mutual customers’ speed to market. LexisNexis Risk Solutions has been a partner of Duck Creek for fourteen years. It offers ten pre-built integrations for its industry-leading solutions. Its integrations are more consistently adopted than others, resulting in quicker implementation time and cost savings for our mutual customers.

Quadient was recognized as Personalized Experiences Solution Partner of the Year for providing a compelling solution integration to better personalize the policyholder experience. Quadient is a leader in customer communications management with integrations available for Duck Creek Policy and Claims. Quadient engaged closely with Duck Creek during 2023 in various co-marketing activities around these integrations, resulting in multiple new sales opportunities for both parties.

Smart Communications was recognized as International Solution Partner of the Year for significantly contributing globally to Duck Creek’s business. Smart Communications is a recognized global leader in customer communications management. In 2023, their team stood out by collaborating extensively with Duck Creek’s team to develop key demonstration integrations jointly and sponsored our first annual customer summit for our APAC region.

Penguin Tech was recognized as Consulting Partner of the Year for making significant contributions to the value of the Duck Creek ecosystem. The Penguin Tech team has over 40 years of combined Duck Creek experience and accelerated the growth of the Duck Creek ecosystem by developing many integrations on behalf of our Solution Partners. These integrations with market leaders have created compelling sales demonstrations and extended the Duck Creek value proposition.

“We are thrilled by the valuable partnerships we’ve formed and our capacity to engage collaboratively with distinguished companies such as Accenture, Aggne, Coforge, Copart, LexisNexis, Quadient, Smart Communications, and Penguin Tech. Together, we are reshaping the landscape of innovation in the insurance industry as we continue delivering top-tier cloud-based solutions paired with exceptional services,” said Mike Jackowski, CEO, Duck Creek Technologies. “It is a privilege to recognize these achievements and commemorate the accomplishments of our partners at our Partner Summit ’23, with an audience comprising hundreds of fellow ecosystem members.”

For more information about these award-winning Duck Creek partners, visit https://www.duckcreek.com/partner/ and these partner websites:

Systems Integrator award winners:

Accenture

Aggne

Coforge

Solution Partner award winners:

Copart

LexisNexis Risk Solutions

Quadient

Smart Communications

Consulting Partner award winner:

Penguin Tech

About Duck Creek Technologies

Duck Creek Technologies is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and Twitter.

Media Contacts:
Carley Bunch
carley.bunch@duckcreek.com

GlobeNewswire Distribution ID 8925918

Posted on

WilsonHCG named No. 1 global RPO provider in HRO Today’s 2023 RPO Baker’s Dozen List

TAMPA, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) — WilsonHCG has been recognized as the No. 1 Recruitment Process Outsourcing (RPO) provider in HRO Today’s 2023 Baker’s Dozen List.

The longest-standing customer satisfaction survey in the RPO industry, HRO Today’s Baker’s Dozen List is designed to highlight the world’s top RPO providers and lends transparency into the RPO partnerships that are most impactful. Providers are rated on a range of factors including breadth of solutions, quality of service and size of deal.

“It’s an honor to be ranked No. 1 in the Baker’s Dozen List,” said John Wilson, CEO at WilsonHCG. “This recognition means so much to us as a business because it’s solely driven by client feedback. It really is a testament to the commitment and care that our people place in our client relationships. I want to say a huge thank you to the team and can’t wait to build on this success as we continue to add even more value to our client partnerships.”

“Since WilsonHCG’s first placement on the HRO Today Baker’s Dozen as a challenger brand, it has focused on great customer service and innovative approaches to recruitment process outsourcing and workforce solutions. It has transitioned from its early days as a challenger to a large and market dominating leader which is helping redefine what success should look like for clients of these service offerings. Remarkably, WilsonHCG’s service orientation has continued to improve as it has grown to one of the largest and most successful companies in the space and we congratulate it and its leadership team on ranking as the top provider on the HRO Today RPO Baker’s Dozen,” said Elliot Clark, CEO of HRO Today.

Visit the HRO Today website here to find more information about the Baker’s Dozen List.

About WilsonHCG
WilsonHCG is an award-winning, global leader in total talent solutions. Operating as a strategic partner, it helps some of the world’s most admired brands build comprehensive talent functions. With a global presence spanning more than 65 countries and six continents, WilsonHCG provides a full suite of configurable talent services including recruitment process outsourcing (RPO), executive search, contingent talent solutions and talent consulting.

TALENT.™ It’s more than a solution, it’s who we are.

www.wilsonhcg.com

Media contact
kirsty.hewitt@wilsonhcg.com

+44 7889901517

813-418-4479

GlobeNewswire Distribution ID 8925480

Posted on

Acino significantly expands presence and capabilities in Latin America through acquisition of M8 Pharmaceuticals

Over 300 M8 employees, product portfolio and pipeline to enhance Acino’s footprint and strategic position in key Latin American markets.

Zurich, Switzerland, Sept. 20, 2023 (GLOBE NEWSWIRE) — Acino, a Swiss pharmaceutical company headquartered in Zurich, today announced that it has entered into an agreement to acquire M8 Pharmaceuticals (M8), a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.

Through this acquisition, Acino will enter the two largest pharmaceutical markets in Latin America, significantly expanding its geographic footprint and strengthening its position in the region, providing a more powerful and comprehensive offering for healthcare professionals and patients. The acquisition will complement Acino’s existing Latin American division, which is based in Panama and operates across eight countries in Central America, the Caribbean, and Ecuador, delivering high-quality medicines to improve people’s health in this key region.

M8, a Montreux Growth Partners portfolio company, has a highly successful record of signing exclusive licensing agreements with large pharmaceutical and biotech companies for the rights to market and commercialize products in Latin America. M8 brings a portfolio of well-known proven brands and innovative products, a best-in-class deal-making platform and an outstanding reputation among its partners. Moreover, it has built a large pipeline across a broad range of key therapeutic areas, including CNS, cardiometabolism, respiratory, gastroenterology, oncology and hematology, and rare diseases.

Andrew Bird, Interim CEO at Acino commented: “This is a transformative deal for Acino, significantly expanding our presence in Latin America and delivering against our overall strategy and stated intention to increase patient’s access to high-quality pharmaceuticals and diversify our footprint in key high-growth markets. We see M8 and Acino as highly complementary offerings, and we are confident that we can use this acquisition as a catalyst to further increase value and accelerate growth for Acino in this key region.”

Joel Barlan, CEO at M8 commented: “This agreement will provide M8 with considerable additional resources, expertise, and access to a much wider geographic footprint, which will further accelerate our growth. We look forward to leveraging the skills and capabilities of both teams to grow the combined business and continue to bring proven and innovative treatments to patients and caregivers throughout Latin America and other emerging markets.”

Dan Turner, Managing Director at Montreux Growth Partners commented: “We could not be more pleased with what M8 has achieved during our ownership. We first invested in the early stages of its development. We were able to bring on board a world-class management team, who have focused the company on patient critical therapeutic areas, with a product portfolio that now includes over 30 leading brands from major pharmaceutical companies around the world. The company has delivered tremendous growth and profitability, while also doing much good for the lives of patients. Acino is the perfect acquirer to continue that history of success”.

The transaction is subject to customary closing conditions, including antitrust clearance, and is expected to be completed by the end of 2023. Banco J.P. Morgan S.A. is acting as exclusive financial advisor, Goodwin LLP as exclusive legal advisor, and PWC as exclusive accounting and tax advisor to Acino. Stifel, Cooley LLP and Credit Suisse, a UBS Group Company acted as advisors to M8.

About AcinoAcino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine, the CIS Region, and Latin America. Acino is part of ADQ, an Abu Dhabi based investment and holding company. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.

About M8 Pharmaceuticals

M8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in Latin America: Brazil and Mexico. We aim to become the preferred pharmaceutical partner for the licensing of high-value innovative and proven therapies across our main therapeutic areas CNS, respiratory, cardiometabolic, immunology, gastroenterology, onco-hematology, and rare diseases. Our mission is to provide the people of Latin America with access to the proven and innovative medicines they need to transform their lives.

About Montreux Growth Partners

Founded in 1993, Montreux Growth Partners has a long history of investing growth capital into category-leading companies that are advancing healthcare and financial technology. It focuses on commercial stage companies which have highly differentiated products, technologies, and services. It is an active and collaborative investor, working closely with the management teams at its portfolio companies.

Attachment

Acino
Larisa Bernstein, Global Head of Communications
larisa.bernstein@acino.swiss

M8 Pharmaceuticals
Joel Barlan, Chief Executive Officer
+52 (55) 4431 2933 
us.wm@moksha8.com

Rafael Ferrer, Vice President of Corporate Development & Strategy
+1 (305) 299 6998
rafael.ferrer@m8pharma.com

GlobeNewswire Distribution ID 8925525

Posted on

Winners Announced in 2023 Stevie Awards for Great Employers

Bank of America and Globe Telecom Among Top Winners

Winners in the 8th Annual Stevie Awards for Great Employers Were Announced at a Ceremony in NYC

The 2023 Stevie Awards for Great Employers recognize the world’s best employers and the human resources professionals, teams, achievements, and HR-related products and suppliers who help to create and drive great places to work.

FAIRFAX, Va., Sept. 19, 2023 (GLOBE NEWSWIRE) — Winners in the 2023 Stevie® Awards for Great Employers, an international competition, were announced on Monday, September 18 during a gala event in New York City. The awards recognize the world’s best employers and the human resources professionals, teams, achievements, and HR-related products and suppliers who help to create and drive great places to work.

A complete list of Gold, Silver, and Bronze Stevie Award winners by category is available at http://www.StevieAwards.com/HR.

A diverse group of organizations and individuals around the world are among those recognized. The organization that won the Grand Stevie Award for Most Honored Organization of the Year is Bank of America of Charlotte, NC, with seven Gold, seven Silver, and seven Bronze Stevie Awards wins totaling 45.5 points. Organization of the Year goes to the organization with the most award points, with each Gold Stevie win counting for three points, each Silver Stevie win for two points, and each Bronze Stevie for one-and-a-half points.

The Grand Stevie Award for the Highest-Rated Nomination of the Year goes to Globe Telecom Inc. of Taguig City, Philippines for their nomination of Ato Jiao for Chief HR Officer of the Year, which received an average score from the judges of 9.5 out of a possible 10.

Leading winners of Gold Stevie Awards include Bank of America (7), Cathay United Bank (5), IBM (4), Tata Consultancy Services (4), Tech Mahindra (4), Dimes Sanayi ve Ticaret A.Ş. (3), Enerjisa Enerji (3), Product Madness (3), TELUS International (3), Akbank T.A.S. (2), American Systems (2), Ayala Land Inc. (2), BlueSky Personnel Solutions (2), Borusan (2), DHL Global Forwarding, Freight (2), FedEx (2), Globe Telecom (2), GoHealth (2), Golden Hour Veterinary Telemedicine (2), Kordsa Teknik Tekstil A.Ş. (2), Saint-Gobain North America (2), Siemens AG (2), and Top Hat (2).

More than 1,000 nominations by organizations from 28 nations were evaluated in this year’s competition. Winners were determined by the average scores of more than 125 professionals worldwide acting as judges.

Stevie Award winners in the 31 Employer of the Year categories were determined by a unique blending of the ratings of professionals and the votes of the general public.

The Stevie Awards for Great Employers recognize achievement in many facets of the workplace. Categories include:

  • Employer of the Year Awards
  • HR Achievement Awards
  • HR Individual Awards
  • HR Team Categories
  • Solution Provider Awards
  • Solutions, Implementations, and Training Programs or Media Awards
  • Thought Leadership Categories
  • COVID-19 Response Awards

The awards are presented by the Stevie Awards, which organizes eight of the world’s leading business awards programs including The International Business Awards® and The American Business Awards®.

About the Stevie Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

A sponsor of the 8th annual Stevie Awards for Great Employers is HiBob.

Marketing Contact
Nina Moore
Nina@StevieAwards.com
+1 (703) 547-8389

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/06939e25-fba1-4760-aacd-ed60700c9173

GlobeNewswire Distribution ID 8924230

Posted on

Impulse Dynamics Announces Leadership Changes

Jason Spees Appointed to Chief Executive Officer — Shlomi Nachman To Be Chairman and John Liddicoat To Join the Board of Directors — Expanding Depth of Medical Device Industry Leadership and Track Record of Driving Commercialization Success With Advanced Technology

MARLTON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership appointments, including Jason Spees to Chief Executive Officer, Shlomi Nachman to Chairman of the Board, and John Liddicoat, M.D., as a member of the Board of Directors. Spees was recently President and Chief Commercial Officer at Impulse Dynamics and brings a depth of medical device industry experience from commercial leadership roles. Nachman most recently was the Company Group Chairman at Johnson & Johnson, overseeing the Cardiovascular and Specialty Solutions & Vision Group. Liddicoat most recently served as Executive Vice President and President of the Americas Region and Enterprise Technology & Innovation function at Medtronic.

“I am pleased to lead the Impulse Dynamics team, focusing on a strong commercialization strategy and our commitment to an ongoing pace of innovation to change the course of treatment for patients living with heart failure,” said Spees. “We find ourselves in a unique position to capitalize on robust clinical data and a lineup of cutting-edge technologies, exemplified by the Integra-D™ trial featuring the groundbreaking single device that integrates our CCM® technology with implantable cardioverter defibrillator (ICD) technology. I look forward to working closely with the board and the leadership team to optimize the company for its next phase of commercial acceleration.”

“I am honored to join the board of an organization that has showcased substantial contributions to the advancement of heart failure treatment,” said Shlomi Nachman. “Over 64 million people suffer from heart failure, and many of those treated are not experiencing the higher quality of life they deserve. With CCM therapy and its future product pipeline, we are in the exciting position of being able to help millions of these patients to feel better and lead fuller lives,” Nachman added. “I’m looking forward to working with the leadership team and the board to ensure a direct path to ongoing innovation and commercial success.”

“I’ve been watching Impulse Dynamics and its technology from the sidelines for many years, and I am excited to now be able to join the team,” said Liddicoat. “I look forward to working with a strong leadership team to lead innovation-driven growth as we aim to enhance the standard of care for heart failure patients across the globe.”

Jason Spees joined the company as President and Chief Commercial Officer in July 2021. He brings more than two decades of successful leadership roles in the medical device industry. Spees was most recently Senior Vice President of Sales and Marketing for Biotronik in the areas of cardiac rhythm management, cardiovascular intervention, peripheral vascular intervention, diagnostics, and digital health. Prior to Biotronik, Spees was the Chief Commercial Officer of Preventice Solutions, along with multiple leadership positions, including Vice President of Sales for Boston Scientific. He holds a B.S. in Operations Research and Engineering from the United States Air Force Academy and an M.A. in Public Management – Finance from the University of Maryland.

Shlomi Nachman was the Company Group Chairman of Cardiovascular and Specialty Solutions and Visions Group within Johnson & Johnson’s Medical Devices sector. Nachman was a member of the Medical Devices Group Operating Committee, where he led a diverse portfolio of six medical device businesses, including Electrophysiology, Neurovascular Intervention, Ear, Nose & Throat, Breast Aesthetics, Optometry and Ophthalmology. Before that, Nachman had various roles with increased scope and responsibilities, including Worldwide President of Biosense Webster and Cordis. His career at Johnson & Johnson spanned over 27 years, comprising multiple leadership positions with a proven track record of success that has recognized the ability to drive growth, innovation, and architect business turnarounds. Additionally, Nachman has accrued deep knowledge in all aspects of medical devices, such as general management, strategy, L&A, finance, product development, operations, sales and marketing, and research and development. Nachman was born in Israel and holds a B.S. in Management and Economics from the Technion Institute, as well as a diploma in electrical engineering from the Amal Technical School.

John Liddicoat brings a history of transformational leadership focused on execution. He spent 16 years at Medtronic, driving the strategic direction and global operations of increasing size and scope, including the Structural Heart, Cardiac Rhythm, and Heart Failure businesses. In his most recent role as Executive Vice President and President of the Americas region and the Enterprise Innovation and Technology function, he was responsible for designing and implementing go-to-market strategies to deliver above-market growth across North and South America. Liddicoat graduated medical school from the University of Chicago, completed a residency in general and cardiothoracic surgery at Johns Hopkins Hospital, and served on the faculty of Harvard Medical School. An innovator and entrepreneur, he has also served as a consultant to venture capital firms and early-stage medical device companies.

About the Optimizer® Integra CCM-D™ System and CCM® Therapy

The Optimizer Integra CCM-D System is an investigational device that combines CCM therapy and ICD therapy into one device. This device is being used in an FDA-approved Investigational Device Exemption (IDE) study and is not available for sale in the United States.

Impulse Dynamics currently offers the Optimizer system that is FDA-approved and CE-marked. The Optimizer system delivers CCM therapy — the company’s proprietary technology — to the heart. CCM therapy has been designed by Impulse Dynamics to improve the heart’s contraction, allowing more oxygen-rich blood to be pushed out through the body. CCM therapy is indicated to improve the 6-minute hall walk, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM therapy delivers non-excitatory electrical pulses from the implantable Optimizer device in a manner designed to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during their absolute refractory period. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and CCM therapy has been published in more than 120 peer-reviewed journal articles.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com or follow the company on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and CCM therapy combined with an ICD delivered via a single device (CCM-D), and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Integra CCM-D System and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

Rohan More, Global Vice President of Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

Ian Segal, Public and Media Relations Manager
Impulse Dynamics
856-642-9933
isegal@impulsedynamics.com

GlobeNewswire Distribution ID 8924737